指尖采血型POCT新冠试剂推出,更快捷更简便
来源: 奥咨达医疗技术服务 作者: 2020年07月09日 10:31

EurofinsPOCT鉴别

是否触过COVID-19病毒


本文摘译自MASSDEVICE 2020年7月1日

以下为详文




法国Eurofins公司近日宣布推出一款POCT设备,用以鉴别过去是否曾接触过COVID-19病毒。



据报道,基于血清学,指尖穿刺试验在症状出现后19天进行抗体检测,灵敏度为94.5%,仅需10分钟就出结果。


Eurofins公司CE认证的INgezim双重识别免疫色谱分析法通过使用核蛋白作为抗原检测抗体,针对SARS-CoV-2在单一血液、血清和血浆样本中的特异性,确定总抗体(IgG、IgA和IgM)是否存在。


虽然这些测试为医疗保健专业人员所使用,尚不能用于自我诊断,但是用于试验的试剂盒包括了进行手指穿刺试验所需的所有材料,具备在检验科室外进行检验分析的可能。


根据公布的结果,用以验证检测结果的400多份血清样本没有检测到与其他呼吸道冠状病毒的交叉反应,Eurofins公司确认该产品特异性指标为99.3%






原文:



Eurofins launches 10-minute COVID-19 exposure testing device

JULY 1, 2020 BY SEAN WHOOLEY LEAVE A COMMENT


Eurofins (Paris:ERF.PA) announced today that it launched its rapid point-of-care testing devices to identify past exposure to COVID-19.


The serology-based, finger-prick tests detect antibodies with a sensitivity of 94.5% from 19 days following the onset of symptoms, with results coming in just 10 minutes, according to a news release.


Eurofins’ CE-Marked INgezim dual-recognition immunochromatographic assays determine the presence of total antibodies (IgG, IgA and IgM) specific to SARS-CoV-2 in a single blood, serum and plasma sample by using nucleoprotein as an antigen to detect the antibodies.


Kits for the assay include all materials needed to perform the finger-prick test, with analysis capable of being performed outside a laboratory, although the tests are intended for use by healthcare professionals and not for self-diagnosis.


According to the release, more than 400 sera samples were observed to validate the assays, as no cross-reactivity with other respiratory coronaviruses was detected and Eurofins determined a specificity of 99.3%.


本文著作权属原创者所有,不代表本站立场。我们转载此文出于传播更多资讯之目的,如涉著作权事宜请联系删除。